FASE II STUDY WITH BORTEZOMIB, RITUXIMAB AND BENDAMUSTIN -BRB- FOR NON-HODGKIN LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIAS PATIENTS AT FIRST RELAPSE
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2018
Price : $35 *
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Rituximab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 06 Apr 2018 Planned End Date changed from 1 Dec 2020 to 1 Jun 2020.
- 06 Apr 2018 Status changed from recruiting to active, no longer recruiting.